These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Platelet-activating factor in septic shock. Koltai M; Hosford D; Braquet PG New Horiz; 1993 Feb; 1(1):87-95. PubMed ID: 7922397 [TBL] [Abstract][Full Text] [Related]
25. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock. Martínez C; Juarranz Y; Abad C; Arranz A; Miguel BG; Rosignoli F; Leceta J; Gomariz RP J Leukoc Biol; 2005 May; 77(5):729-38. PubMed ID: 15661828 [TBL] [Abstract][Full Text] [Related]
26. Complement activation in septic shock due to gram-negative and gram-positive bacteria. León C; Rodrigo MJ; Tomasa A; Gallart MT; Latorre FJ; Rius J; Brugués J Crit Care Med; 1982 May; 10(5):308-10. PubMed ID: 6918253 [TBL] [Abstract][Full Text] [Related]
27. Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii. Miech RP Ann Pharmacother; 2005 Sep; 39(9):1483-8. PubMed ID: 16046483 [TBL] [Abstract][Full Text] [Related]
28. The current management of septic shock. Russel JA Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911 [TBL] [Abstract][Full Text] [Related]
29. Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade. Giroir BP Crit Care Med; 1993 May; 21(5):780-9. PubMed ID: 8482101 [TBL] [Abstract][Full Text] [Related]
30. Anti-inflammatory cytokine levels in patients with septic shock. Kasai T; Inada K; Takakuwa T; Yamada Y; Inoue Y; Shimamura T; Taniguchi S; Sato S; Wakabayashi G; Endo S Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):34-42. PubMed ID: 9434313 [TBL] [Abstract][Full Text] [Related]
32. [The role of cell adhesion molecules and proinflammatory mediators in the pathogenesis of endotoxin adult respiratory distress syndrome]. Lazarov S; Balutsov M; Ianev E Vutr Boles; 2000; 32(4):18-24. PubMed ID: 11688326 [TBL] [Abstract][Full Text] [Related]
34. [Physiopathology of myocardial dysfunction in septic shock]. Thyrault M; Chemla D; Coirault C; Lecarpentier Y Arch Mal Coeur Vaiss; 1993 Mar; 86(3):349-57. PubMed ID: 8215770 [TBL] [Abstract][Full Text] [Related]
35. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019 [TBL] [Abstract][Full Text] [Related]
36. [Present possibilities of therapy of septic shock in surgical patients]. Vyhnánek F; Lochmann O Cesk Epidemiol Mikrobiol Imunol; 1992 Sep; 42(3):105-15. PubMed ID: 1339601 [TBL] [Abstract][Full Text] [Related]
37. [Sepsis and organ failure--its pathogenesis and treatment]. Hanasawa K; Kodama M Nihon Geka Gakkai Zasshi; 1998 Aug; 99(8):523-7. PubMed ID: 9789288 [TBL] [Abstract][Full Text] [Related]
38. Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria. Roger T; Glauser MP; Calandra T J Endotoxin Res; 2001; 7(6):456-60. PubMed ID: 11753217 [TBL] [Abstract][Full Text] [Related]
39. Cellular and humoral mediators of sepsis syndrome. Stroud M; Swindell B; Bernard GR Crit Care Nurs Clin North Am; 1990 Jun; 2(2):151-60. PubMed ID: 2192724 [TBL] [Abstract][Full Text] [Related]